NEURO-ONCOLOGY
Scope & Guideline
Transforming Research into Hope for Patients
Introduction
Aims and Scopes
- Clinical Trials and Treatment Strategies:
The journal emphasizes the importance of clinical trials and innovative treatment strategies for brain tumors, including glioblastoma, meningioma, and pediatric CNS tumors. This includes studies on new drugs, combination therapies, and the effectiveness of existing treatments. - Molecular and Genetic Studies:
Research focusing on the molecular and genetic underpinnings of brain tumors is a core area of interest. This includes studies on genetic mutations, epigenetic modifications, and the identification of biomarkers that can inform prognosis and therapy. - Neuroimaging and Radiomics:
The journal publishes research involving advanced neuroimaging techniques and radiomics, which assess tumor characteristics and predict treatment responses. This includes the integration of machine learning and AI in imaging analysis. - Psychosocial Aspects and Quality of Life:
Recognizing the impact of brain tumors on patients' quality of life, the journal includes studies that explore psychosocial factors, neurocognitive outcomes, and supportive care strategies. - Tumor Microenvironment and Immunology:
Research on the tumor microenvironment and its interaction with immune cells is increasingly highlighted, focusing on how these interactions influence tumor growth, treatment resistance, and potential immunotherapeutic approaches.
Trending and Emerging
- Immunotherapy and Targeted Therapies:
A significant increase in studies related to immunotherapy and targeted therapies is evident, reflecting a shift toward personalized medicine in the treatment of glioblastoma and other CNS tumors. - Liquid Biopsy and Minimal Residual Disease Detection:
Research on liquid biopsies and their role in monitoring treatment responses and detecting minimal residual disease is gaining traction, providing a non-invasive method to track tumor dynamics. - AI and Machine Learning Applications:
The integration of artificial intelligence and machine learning in neuro-oncology research is trending, particularly in imaging analysis and prognostic modeling, enhancing diagnostic accuracy and treatment planning. - Neurocognitive Outcomes and Quality of Life Research:
There is a growing emphasis on understanding neurocognitive outcomes and quality of life for patients undergoing treatment for brain tumors, highlighting the psychosocial aspects of cancer care. - Tumor Microenvironment Studies:
An increasing focus on the tumor microenvironment and its role in tumor biology and treatment resistance is emerging, with research exploring how cellular interactions within the microenvironment influence therapeutic outcomes.
Declining or Waning
- Conventional Chemotherapy Studies:
There is a noticeable decline in studies focusing solely on conventional chemotherapy approaches, as interest shifts towards targeted therapies and immunotherapies that offer more personalized treatment options. - Basic Histopathology Reports:
The frequency of basic histopathology studies has decreased, possibly due to a growing focus on molecular characterization and advanced imaging techniques that provide more detailed insights into tumor biology. - Epidemiological Studies:
While epidemiological studies are still relevant, there appears to be a waning interest in broad epidemiological analyses in favor of more targeted studies that explore specific genetic or molecular factors influencing tumor behavior. - Radiotherapy Alone Studies:
Research focusing only on radiotherapy without exploring combination therapies or advanced techniques is less prevalent, as current trends emphasize integrated treatment strategies. - Studies on Adult Brain Tumors:
The proportion of studies focused exclusively on adult brain tumors is declining as there is a growing emphasis on pediatric neuro-oncology, reflecting increased awareness and research funding in this area.
Similar Journals
CANCER SCIENCE
Unlocking the mysteries of cancer through rigorous research.Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.
Journal of Bone Oncology
Bridging Science and Practice in Bone Cancer CareJournal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.
Gastric Cancer
Unveiling Innovations in Gastric Cancer Treatment.Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.
Neuro-Oncology Advances
Pioneering insights for better outcomes in nervous system tumors.Neuro-Oncology Advances, published by Oxford University Press, is an esteemed open-access journal dedicated to advancing the field of neuro-oncology. Established in 2019, the journal has quickly gained recognition for its commitment to disseminating high-quality research, evidenced by its impressive Q1 rankings in Neurology (Clinical), Oncology, and Surgery categories as of 2023. With a rigorous peer-review process and a focus on innovative findings, Neuro-Oncology Advances serves as a vital platform for researchers, practitioners, and students seeking to stay at the forefront of developments in the diagnosis and treatment of nervous system tumors. The journal is accessible globally, ensuring that critical knowledge is available to help improve clinical outcomes and foster collaboration within this crucial interdisciplinary field.
INTERNATIONAL JOURNAL OF CANCER
Shaping the future of oncology through rigorous research.INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.
Gastrointestinal Tumors
Fostering Global Collaboration in Gastrointestinal StudiesGastrointestinal Tumors is a reputable, peer-reviewed journal dedicated to advancing knowledge in the field of gastrointestinal oncology. Published by KARGER, this journal has been a pivotal platform since its transition to Open Access in 2014, ensuring that research findings are accessible to a global audience of researchers, clinicians, and students engaged in this vital area of study. With an emphasis on innovative research, clinical studies, and comprehensive reviews, Gastrointestinal Tumors aims to bridge gaps in knowledge and foster discussions that will inform and enhance clinical practices. The journal's commitment to excellence reflects the rising importance of gastrointestinal health in medical research, making it an essential resource for anyone seeking to stay at the forefront of this rapidly evolving field. Based in Basel, Switzerland, it is positioned within a strong academic community, and continues to influence the landscape of gastrointestinal cancer research.
CNS DRUGS
Advancing Neuroscience through Innovative PharmacotherapyCNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.
Journal of Hematology & Oncology
Unlocking Innovations in Blood Disorders and Cancer ResearchJournal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.
World Journal of Clinical Oncology
Fostering Collaboration in the Fight Against CancerWorld Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.
Oncology Research and Treatment
Uniting researchers to combat cancer effectively.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.